<DOC>
	<DOCNO>NCT00659347</DOCNO>
	<brief_summary>The primary objective placebo-controlled trial evaluate effectiveness safety DOV 21,947 two oral dose level .</brief_summary>
	<brief_title>Efficacy Safety DOV 21,947 Treatment Major Depressive Disorder</brief_title>
	<detailed_description>DOV 21,947 investigational drug develop treatment depression . The purpose study evaluate safety effectiveness flexible dosing schedule DOV 21,947 ( 25 mg twice daily two week , 50 mg twice daily four week compare placebo ) treatment major depressive disorder . Information side effect may occur also collect . The efficacy evaluation base change total MADRS HAMD-17 score randomization week 9 .The secondary objective determine DOV 21,947 improves quality life patient MDD compare placebo</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>1 . Males females 18 65 year age ( inclusive ) . 2 . Either outpatients inpatient diagnose major depressive disorder ( MDD ) accord Diagnostic Statistical Manual Mental Disorders ( DSMIVTR , see Appendix 3 ) MINI International Neuropsychiatric Interview ( MINI ) . 3 . Patients recurrent depressive episode least 2 month duration . Patients must previously respond ( significant clinical improvement judge Principal Investigator ) least one antidepressant treatment . 4 . HAMD17 total score * 22 severity score least 2 Item 1 Placebo RunIn Visit Baseline/Day 1 Visit . 5 . HAMD17 score reduction â‰¤ 15 % Placebo RunIn Visit Baseline/Day 1 Visit . 6 . HAMA total score &lt; 17 Screening Visit . 1 . Patients HAMD17 total score reduction 15 % Placebo RunIn Visit Baseline/Day 1 Visit ( placebo responder ) . 2 . Patients medical history MDD consistently respond significantly adequate treatment regimen monoamine oxidase ( MAO ) inhibitor . 3 . Patients know antidepressant treatmentresistant . Patients define treatmentresistant past fail adequate antidepressant treatment ( dose level approve product label administer least 4 week ) two different pharmacological class ( e.g. , TCA , SSRI , SNRI , MAOI , etc ) . Failure respond adequate antidepressant treatment define absence least 50 % improvement symptoms patient report document history , lack significant clinical improvement Principal Investigator 's discretion . 4 . Patients medical history MDD consistently respond significantly electroconvulsive shock therapy ( ECT ) ECT within year prior Screening Visit regardless outcome . 5 . Patients psychotic depression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>